Nanomaterials Drive In Vivo CAR Immune Cells Engineering
Advanced Materials · 2026
DOI: 10.1002/adma.74058 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Materials, 2026. Verfasst von Meifen Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Interventional Radiology, School of Biomedical Engineering & The Second Affiliated Hospital, Guangzhou Medical Unive…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Nanostructures, Cell Engineering, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangzhou Science and Technology Plan Project.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) immune cell therapy has emerged as a cornerstone of modern cell‐based medicine, demonstrating potent clinical efficacy against a range of malignant tumors and autoimmune diseases. Nevertheless, conventional ex vivo CAR immune cell manufacturing is hindered by complexity, high costs, and significant inter‐individual variability, which have limited its broad clinical application. These bottlenecks have prompted a paradigm shift toward in vivo CAR engineering, wherein nanocarriers directly deliver genetic material to circulating or tissue‐resident immune cells, substantially simplifying the production process. This review first outlines the evolution of CAR immune cell therapy and key limitations of ex vivo approaches and then examines major delivery platforms for in vivo approaches. Comparative analyses are presented across delivery efficiency, cellular tropism, and expression kinetics, with particular emphasis on delineating the mechanistic distinctions and application boundaries between transient and durable expression strategies. We further dissect the critical challenges, including receptor‐mediated non‐specific immune activation, nanocarrier‐associated immunogenicity constraining repeated administration, and delivery barriers imposed by the solid tumor microenvironment. Finally, the intrinsic trade‐off between therapeutic durability and biosafety across distinct delivery platforms is discussed, along with the necessity that their clinical translation hinges on systematic optimization of delivery precision, immune compatibility, and expression controllability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Minimally Invasive Interventional Radiology, School of Biomedical Engineering & The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, P. R. China.
- The First Clinical College, Guangzhou Medical University, Guangzhou, P. R. China.
- Guangdong Provincial Key Laboratory of Allergy and Clinical Immunology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, P. R. China.
ORCID-Profile: Weisheng Guo
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Guangzhou Science and Technology Plan Project
- Major Project of Guangzhou National Laboratory
- Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project
Zitieren
APA
Luo, M., Liao, K., Chang, J., Xie, J., Liang, X. J., Lei, Q., & Guo, W. (2026). Nanomaterials Drive In Vivo CAR Immune Cells Engineering. Advanced Materials. https://doi.org/10.1002/adma.74058
Vancouver
Luo M, Liao K, Chang J, Xie J, Liang XJ, Lei Q, et al. Nanomaterials Drive In Vivo CAR Immune Cells Engineering. Advanced Materials. 2026. doi:10.1002/adma.74058
BibTeX
@article{Luo2026,
author = {Luo, Meifen and Liao, Kai and Chang, Jinxi and Xie, Junze and Liang, Xing-Jie and Lei, Qi and Guo, Weisheng},
title = {Nanomaterials Drive In Vivo CAR Immune Cells Engineering},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.74058}
}
EUVIMED